Equitable State Allocation: Promising Practices for Promoting Utilization of COVID-19 Monoclonal Antibody Treatments

Driven by limited supply of monoclonal antibody (mAb) therapies and sharply rising demand for mAb treatment during the Delta variant-driven spike in cases, the Federal government shifted to facilitating state- and territory-coordinated allocation of mAb therapies. To support state leaders in promoting equitable access to mAb therapies—as well as flexibility in allocation processes amid shifting supply and demand—this issue brief outlines promising approaches for states to address key considerations around data tracking, patient prioritization, distribution logistics, and community engagement.